{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:59:21Z","timestamp":1790783961755,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To investigate the treatment effect of adjuvant chemotherapy for stage I ovarian clear cell carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>We searched Cochrane, PubMed, International Standard Randomised Controlled Trial Number registry, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform, and Ichushi-Web to January 22, 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS OF STUDY SELECTION:<\/jats:title>\n                    <jats:p>We included randomized controlled trials (RCTs) and non-RCTs that included more than 50 patients with stage I ovarian clear cell carcinoma. The primary and secondary outcomes were disease-free survival and overall survival, respectively. We performed a meta-analysis of the stage-adjusted hazard ratios (HRs) of adjuvant chemotherapy compared with placebo or no intervention. The substage-related heterogeneity of effects was also assessed. A meta-analysis of proportions was also conducted to assess 5-year disease-free survival and 5-year overall survival. Risk of bias was assessed with the Risk of Bias in Non-randomized Studies of Interventions tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TABULATION, INTEGRATION, AND RESULTS:<\/jats:title>\n                    <jats:p>\n                      Because no RCTs reported HRs for the ovarian clear cell carcinoma subgroup, data from nine non-RCTs were analyzed. The pooled substage-adjusted HR for disease-free survival associated with use of chemotherapy was 0.47 (95% CI, 0.29\u20130.74) and that for overall survival was 0.66 (95% CI,0.43\u20131.00). Heterogeneity in the effect by substage was not evident for either disease-free survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      for subgroup difference=.91) or overall survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.60). The pooled 5-year disease-free survival was 0.80 (95% CI, 0.65\u20130.89) for stage I overall, 0.95 (95% CI, 0.47\u20131.0) for stage IA, and 0.61 (95% CI, 0.47\u20130.74) for stage IC. The estimated number needed to treat was 10.2 (95% CI, 5.8\u201318.6) for stage I overall, 40.8 (95% CI, 3.9\u2013infinity) for stage IA, and 5.2 (95% CI, 3.9\u20137.8) for stage IC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Adjuvant chemotherapy improves disease-free survival and may prolong overall survival in patients with stage I ovarian clear cell carcinoma. Available evidence suggests that recurrence is reduced by approximately 50%. Treatment decisions should consider the baseline recurrence risks and absolute benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>PROSPERO, CRD42024562486.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000006116","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:00:52Z","timestamp":1771538452000},"page":"344-354","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant Chemotherapy in Stage I Ovarian Clear Cell Carcinoma"],"prefix":"10.1097","volume":"147","author":[{"given":"Yoshihide","family":"Inayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Higashiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rin","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mana","family":"Taki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yamanoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Hamanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki A.","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"R1-20260930","doi-asserted-by":"crossref","first-page":"m3773","DOI":"10.1136\/bmj.m3773","article-title":"Treatment of epithelial ovarian cancer","volume":"371","author":"Kuroki","year":"2020","journal-title":"BMJ"},{"key":"R2-20260930","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10147-024-02473-8","article-title":"Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021","volume":"29","author":"Nakai","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"R3-20260930","doi-asserted-by":"crossref","first-page":"oyae325","DOI":"10.1093\/oncolo\/oyae325","article-title":"Ovarian clear cell carcinoma: open questions on the management and treatment algorithm","volume":"30","author":"Rosso","year":"2025","journal-title":"Oncologist"},{"key":"R4-20260930","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2011.06.039","article-title":"Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype","volume":"310","author":"Mandai","year":"2011","journal-title":"Cancer Lett"},{"key":"R5-20260930","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2017.08.004","article-title":"An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: an NRG Oncology\/Gynecologic Oncology Group experience","volume":"147","author":"Oliver","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R6-20260930","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ygyno.2021.06.033","article-title":"Clear cell carcinoma of the ovary: epidemiology, pathological and biological features, treatment options and clinical outcomes","volume":"162","author":"Gadducci","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R7-20260930","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1111\/jog.15767","article-title":"Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: annual patient report for 2020 and annual treatment report for 2015","volume":"49","author":"Yoshino","year":"2023","journal-title":"J Obstet Gynaecol Res"},{"key":"R8-20260930","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/og9.0000000000000031","article-title":"Adjuvant chemotherapy for stage I ovarian clear cell carcinoma","volume":"1","author":"Horikawa","year":"2024","journal-title":"O&G Open"},{"key":"R9-20260930","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/IGC.0b013e31823fd413","article-title":"Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients","volume":"22","author":"Takada","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"R10-20260930","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ygyno.2018.04.567","article-title":"Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: patterns of use and outcomes","volume":"150","author":"Nasioudis","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R11-20260930","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2019.12.045","article-title":"Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: a systematic review and meta-analysis","volume":"157","author":"Bogani","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R12-20260930","doi-asserted-by":"crossref","first-page":"811638","DOI":"10.3389\/fonc.2022.811638","article-title":"Impact of adjuvant chemotherapy on FIGO stage I ovarian clear cell carcinoma: a systematic review and meta-analysis","volume":"12","author":"Yin","year":"2022","journal-title":"Front Oncol"},{"key":"R13-20260930","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/j.jpainsymman.2024.06.002","article-title":"Understanding the number needed to treat","volume":"68","author":"Davis","year":"2024","journal-title":"J Pain Symptom Manage"},{"key":"R14-20260930","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12916-017-0875-8","article-title":"Number needed to treat (NNT) in clinical literature: an appraisal","volume":"15","author":"Mendes","year":"2017","journal-title":"BMC Med"},{"key":"R15-20260930","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R16-20260930","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R17-20260930","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R18-20260930","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/biom.13197","article-title":"Optimal approximate conversions of odds ratios and hazard ratios to risk ratios","volume":"76","author":"VanderWeele","year":"2020","journal-title":"Biometrics"},{"key":"R19-20260930","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ygyno.2014.12.006","article-title":"Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion","volume":"136","author":"Matsuo","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R20-20260930","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jclinepi.2018.01.012","article-title":"GRADE guidelines: 18: how ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence","volume":"111","author":"Sch\u00fcnemann","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"R21-20260930","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0002-9378(80)90024-1","article-title":"The role of adjuvant therapy in stage I ovarian cancer","volume":"138","author":"Hreshchyshyn","year":"1980","journal-title":"Am J Obstet Gynecol"},{"key":"R22-20260930","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199004123221501","article-title":"Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials","volume":"322","author":"Young","year":"1990","journal-title":"N Engl J Med"},{"key":"R23-20260930","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/oxfordjournals.annonc.a059355","article-title":"Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P): G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica","volume":"6","author":"Bolis","year":"1995","journal-title":"Ann Oncol"},{"key":"R24-20260930","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/A:1008399414923","article-title":"Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument","volume":"11","author":"Trop\u00e9","year":"2000","journal-title":"Ann Oncol"},{"key":"R25-20260930","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/95.2.125","article-title":"International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer","volume":"95","author":"Colombo","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R26-20260930","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jnci\/95.2.105","article-title":"International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant Chemo Therapy in Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma","volume":"95","author":"Trimbos","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R28-20260930","first-page":"1506","article-title":"Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study","volume":"20","author":"Takano","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"R29-20260930","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/IGC.0b013e31825c7cbe","article-title":"Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: is it necessary for stage IA?","volume":"22","author":"Mizuno","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"R30-20260930","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/IGC.0000000000000178","article-title":"Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary","volume":"24","author":"Suzuki","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"R31-20260930","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ygyno.2017.07.128","article-title":"Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma?","volume":"147","author":"Hogen","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R32-20260930","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1093\/annonc\/mdx525","article-title":"Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results cohort study, 2000-2013","volume":"28","author":"Oseledchyk","year":"2017","journal-title":"Ann Oncol"},{"key":"R33-20260930","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(24)00139-9","article-title":"Recommendations for accurate reporting in medical research statistics","volume":"403","author":"Mansournia","year":"2024","journal-title":"Lancet"},{"key":"R34-20260930","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMsr077003","article-title":"Statistics in medicine\u2013reporting of subgroup analyses in clinical trials","volume":"357","author":"Wang","year":"2007","journal-title":"N Engl J Med"},{"key":"R35-20260930","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMe1906088","article-title":"The precision of evidence needed to practice \u201cprecision medicine.\u201d","volume":"380","author":"Hunter","year":"2019","journal-title":"N Engl J Med"},{"key":"R36-20260930","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bmj.318.7197.1548","article-title":"Numbers needed to treat derived from meta-analyses\u2013sometimes informative, usually misleading","volume":"318","author":"Smeeth","year":"1999","journal-title":"BMJ"},{"key":"R37-20260930","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1136\/ijgc-2022-003935","article-title":"Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation","volume":"32","author":"Manning-Geist","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"R38-20260930","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s10147-024-02561-9","article-title":"Comorbid thrombosis as an adverse prognostic factor in patients with ovarian clear cell carcinoma regardless of staging","volume":"29","author":"Yamaguchi","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"R39-20260930","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/MLR.0000000000000073","article-title":"Comparison of SEER treatment data with Medicare claims","volume":"54","author":"Noone","year":"2016","journal-title":"Med Care"},{"key":"R40-20260930","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms","volume":"380","author":"Harter","year":"2019","journal-title":"N Engl J Med"},{"key":"R41-20260930","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ygyno.2006.06.013","article-title":"Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study","volume":"102","author":"Bell","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R42-20260930","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/bmj.311.7016.1356","article-title":"An evidence based approach to individualising treatment","volume":"311","author":"Glasziou","year":"1995","journal-title":"BMJ"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:01:18Z","timestamp":1790780478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006116"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006116","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2025-06-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}